- Home
- ALKS
ALKS
Alkermes plc
as 12-20-2024 4:00pm EST
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
| Founded: | 1987 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 4 |
| Market Cap: | 4.9B | IPO Year: | 1991 |
| Target Price: | $35.42 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.97 | EPS Growth: | 55.25 |
| 52 Week Low/High: | $22.90 - $32.88 | Next Earning Date: | 02-13-2025 |
| Revenue: | $1,505,121,000 | Revenue Growth: | -5.37% |
| Revenue Growth (this year): | -7.48% | Revenue Growth (next year): | -6.43% |
Stock Insider Trading Activity of Alkermes plc (ALKS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Dec 9 '24 | Sell | $32.07 | 61,151 | $1,961,406.09 | 47,576 | |
| LAURENCIN CATO T | ALKS | Director | Dec 8 '24 | Sell | $31.85 | 2,691 | $85,708.35 | 23,013 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Dec 5 '24 | Sell | $31.50 | 9,221 | $290,461.50 | 47,576 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Dec 4 '24 | Sell | $30.77 | 14,349 | $441,550.30 | 47,576 | |
| Nichols Christian Todd | ALKS | SVP, Chief Commercial Officer | Nov 27 '24 | Sell | $29.15 | 5,208 | $151,813.20 | 60,703 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Nov 11 '24 | Sell | $30.08 | 58,996 | $1,774,576.08 | 47,576 | |
| Hopkinson Craig C. | ALKS | EVP R&D, Chief Medical Officer | Nov 6 '24 | Sell | $29.53 | 10,471 | $309,168.84 | 47,576 |
Latest Alkermes plc News
ALKS Breaking Stock News: Dive into ALKS Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
Alkermes Insider Sold Shares Worth $1,961,406, According to a Recent SEC Filing
Zacks
15 days ago
Qiagen (QGEN) Down 1.6% Since Last Earnings Report: Can It Rebound?
Zacks
16 days ago
Ultragenyx (RARE) Down 6.8% Since Last Earnings Report: Can It Rebound?
MT Newswires
17 days ago
Alkermes Insider Sold Shares Worth $441,550, According to a Recent SEC Filing
Zacks
17 days ago
Illumina (ILMN) Down 9.3% Since Last Earnings Report: Can It Rebound?
Zacks
22 days ago
Glaxo (GSK) Down 6.6% Since Last Earnings Report: Can It Rebound?
Zacks
23 days ago
Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?
Clinical Trials Arena
25 days ago
Axsome Therapeutics eyes approval after Phase III narcolepsy win
Compare ALKS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALKS Alkermes plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.